Tine Jess MD, MSc, co-author of a recent article about the risk of invasive pneumococcal disease (IPD) in IBD patients, talks with AJG Co-Editor Dr. Paul Moayyedi about the increased risk of IPD as long as 4 years prior to IBD diagnosis, the risk of IPD associated with various IBD drug therapies, including the lack of risk associated with biologic therapies and oral corticosteroids, and whether physicians should be routinely offering the pneumococcal vaccine to IBD patients. (16:28)